Bot.Ax
BOT.AX is a pharmaceutical company that develops and commercializes medical products, primarily generating revenue through the sale of prescription drugs and related therapies.
Business. BOT.AX is a pharmaceutical company that develops and commercializes medical products, primarily generating revenue through the sale of prescription drugs and related therapies.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BOT.AX is a pharmaceutical company that develops and commercializes medical products, primarily generating revenue through the sale of prescription drugs and related therapies.
The company's capital structure is characterized by a current ratio of 4.0, indicating strong short-term liquidity. However, the operating cash flow of -78.58 million AUD and free cash flow of -85.18 million AUD suggest significant cash outflows from operations. The debt-to-equity ratio of 0.29 indicates a relatively low level of leverage, with long-term debt amounting to 23.28 million AUD against total equity of 81.29 million AUD.
Profitability metrics are severely negative, with a return on equity of -106.27% and a return on assets of -66.92%. These figures are well below the typical performance of the pharmaceutical industry, which generally expects positive returns on equity and assets. The company reported a net loss of 86.39 million AUD and an operating loss of 88.02 million AUD, indicating a significant decline in profitability.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the risk associated with the company's revenue streams, as it is entirely dependent on the performance of its pharmaceutical products in its primary market.
The company's growth trajectory is negative, with a net loss of 86.39 million AUD and a significant decline in operating income. The outlook for the current fiscal year is not provided, but the negative operating and free cash flows suggest a challenging period ahead. The company's capital expenditure of -1.05 million AUD indicates a reduction in investment in long-term assets, which may affect future growth potential.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares.
Recent events include a significant net loss and negative cash flows, which are reflected in the financial snapshot. Analysts have provided a mean price target of 0.49 AUD and a median price target of 0.33 AUD, with a mean recommendation of 2.00, indicating a neutral to slightly bearish outlook.
- The company is experiencing significant financial distress, with a net loss of 86.39 million AUD and negative cash flows.
- The capital structure is relatively low in leverage, with a debt-to-equity ratio of 0.29.
- Profitability metrics are severely negative, with a return on equity of -106.27%.
- The company's revenue is concentrated in a single business segment, increasing its exposure to market risks.
- Analysts have a neutral to slightly bearish outlook, with a mean price target of 0.49 AUD.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,02 |
| Revenue | —no estimate | —no estimate | 36,0M AUD |
| Operating income | —no estimate | —no estimate | -58,5M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BOT.AX Market data — financials · 2026-05-27
- Botanix Pharmaceuticals Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Vince P. IppolitoExecutive Chairman of the Board